Major depressive disorder ... remit following adequate antidepressant treatment, while most MDD patients suffer from significant core depressive or residual symptoms during their clinical course.
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...
b For adolescents with major depressive disorder or if OCD, posttraumatic stress disorder, or generalized anxiety disorder is present. c First-line treatment if drug interactions with fluoxetine ...
(NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuronetics, the “Combined Company”) today announced that they have successfully completed the ...
It’s important to speak with your healthcare professional about treatment plans. Anxiety disorders ... The Anxiety and Depression Association of America says even 5 minutes of aerobic exercise ...